Invention Grant
- Patent Title: 1,5-disubstituted 1,2,3-triazoles are inhibitors of RAC/CDC42 GTPases
-
Application No.: US16456641Application Date: 2019-06-28
-
Publication No.: US10947247B2Publication Date: 2021-03-16
- Inventor: Cornelis P. Vlaar , Suranganie Dharmawardhane Flanagan , Eliud Hernandez-O'Farrill , Linette Castillo-Pichardo
- Applicant: UNIVERSITY OF PUERTO RICO
- Applicant Address: US PR San Juan
- Assignee: UNIVERSITY OF PUERTO RICO
- Current Assignee: UNIVERSITY OF PUERTO RICO
- Current Assignee Address: US PR San Juan
- Agency: Barnes & Thornburg LLP
- Agent Alice O. Martin
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D403/14 ; C07D491/048 ; C07D403/04 ; C07D409/14
Abstract:
Compounds are disclosed that inhibit RhoGTPases that are useful for inhibiting hyperprofilerative and neoplastic diseases. Specifically, the compounds inhibit the GTPases Rac and Cdc42 that are overactive or overexpressed in signaling pathways in cancer and metastasis. Methods for treatment of cancer and hyperproliferative diseases are disclosed.
Public/Granted literature
- US20200010475A1 1,5-DISUBSTITUTED 1,2,3-TRIAZOLES ARE INHIBITORS OF RAC/CDC42 GTPASES Public/Granted day:2020-01-09
Information query
